Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with myelofibrosis.
COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis
Recent Articles
House Speaker Pelosi to Release Medicare Drug Pricing Bill
House Speaker Nancy Pelosi (D-CA) is expected to release a bill that would allow the U.S. Secretary of Health and Human Services to negotiate...
Could CRISPR Help Parents of Sick Children Conceive Savior Siblings?
In 2018, He Jiankui, PhD, stirred controversy when he modified the DNA of twin embryos using CRISPR to mitigate HIV risk. Now, investigators are...
Despite Right-to-Try Laws, Most Drug Makers Still Require FDA Reviews
The “Right-to-Try” law, which President Donald Trump signed in May 2018, allows more direct access to experimental drugs for terminally ill patients who have...
Purdue Pharma Files for Bankruptcy
OxyContin manufacturer Purdue Pharma has filed for bankruptcy as part of what will be the first settlement related to the opioid crisis. Under this...
2020 Democratic Presidential Candidates Disagree on Health Care
In the recent Democratic primary debates, the top 2020 Democratic U.S. presidential candidates each proposed vastly different approaches to universal health care.
Candidates in favor...
Current Issue
September 2019, Volume 5, Issue 11
This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.
